Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether treatment with 40mg of Rosuvastatin for 8 weeks will reduce the number of episodes of myocardial ischaemia suffered in subjects with coronary artery disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Evidence of Coronary arterial disease

• Suffering ischaemic episodes/exercise induced ischaemia

• Not taking any cholesterol lowering medication

Exclusion Criteria:

• Unstable angina or heart attack less than one month before trial entry

• Coronary arterial surgery as defined by protocol

• Uncontrolled hypertension, diabetes, hypothyroidism or laboratory values as defined by the protocol.